Cynata Therapeutics Receives approval for acute graft-versus-host disease clinical trial
- Cynata Therapeutics (CYP) receives approval to launch a phase two clinical trial in acute graft-versus-host disease
- The clinical stage biotech company was granted the green light to undertake the trial from Advarra, a central institutional research board (IRB) service provider in the US
- IRB approval is considered an “essential step” in the process of opening clinical study sites and starting trials in humans in America
- Cynata expects the trial will be conducted in around 60 patients at sites across the US, Europe, and Australia
- CynataTherapeutics last traded at 31 cents at 2:47 pm AEDT
